Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue: +36.3%
EPS: +36.0%
Free cash flow: +3.85%
Total debt: −26.6%

Quarter to September 2026, against a year earlier

907.91 5.01 +0.55%

Follow REGN

Alert me

Market cap: $93.4B
P/E: 19.2×
Fwd P/E: 19.2×
Dividend yield: 0.41%
F-score: 5/9
Altman Z: 7.49
Beneish M: −2.53
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. (REGN) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a price to free cash flow of 25.3×. Over the past ten years it has ranged from 0.0× (September 2015) to 257× (June 2015); the current reading is higher than 48% of that period. That is in line with the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/REGN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Regeneron Pharmaceuticals, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/REGN/metrics/price-to-free-cash-flow">Regeneron Pharmaceuticals, Inc. (REGN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	21.4×	(0.71%)
FY2024	21.6×	(17.98%)
FY2023	26.3×	15.94%
FY2022	22.7×	122.12%
FY2021	10.2×	(60.60%)
FY2020	25.9×	26.58%
FY2019	20.5×	(7.84%)
FY2018	22.2×	(43.43%)
FY2017	39.3×	(3.68%)
FY2016	40.8×	(52.37%)

Period	Price to free cash flow	Change
Sep 2026	21.3×	18.55%
Jun 2026	17.9×	(15.41%)
Mar 2026	21.2×	(1.15%)
Dec 2025	21.4×	42.87%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 257×

Ten-year median 25.7×

Current reading's percentile 48

Company	Price to free cash flow
ROIV Roivant Sciences Ltd. compare	n/m
GMAB Genmab A/S Sponsored ADR compare	n/m
MRNA Moderna, Inc. compare	n/m
RVMD Revolution Medicines, Inc. compare	n/m
RPRX Royalty Pharma PLC compare	23.3×
REGN Regeneron Pharmaceuticals, Inc.	25.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	30.4×
ARGX argenex SE compare	41.0×
VRTX Vertex Pharmaceuticals Incorporated compare	42.9×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Regeneron Pharmaceuticals, Inc. (REGN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on REGN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on REGN

Stockrow Weekly